

AMENDMENT

In the Claims:

1. (Previously presented) A method of treating cognitive deficits in learning and memory in individuals in need thereof, the method comprising administering to the individual an effective amount of a mecamylamine or a mecamylamine stereoisomer.
2. (Previously presented) The method of claim 1 wherein the mecamylamine or mecamylamine stereoisomer is dimethylamino mecamylamine.
3. (Previously presented) The method of claim 1, wherein the effective amount of the mecamylamine or mecamylamine stereoisomer is 0.005-1.00 mg/kg/day.
4. (Previously presented) The method of claim 1 in which the cognitive deficits in learning and memory are brought on by therapy using conventional neuroleptic drugs.
5. (Original) The method of claim 1 additionally comprising administration of an atypical neuroleptic drug.
6. (Previously presented) A method of treating cognitive deficits in learning and memory associated with learning disorders in individuals in need thereof, the method comprising administering to the individual an effective amount of a mecamylamine or mecamylamine stereoisomer.
7. (Previously presented) The method of claim 6, wherein the mecamylamine or mecamylamine stereoisomer is dimethylamino mecamylamine.
8. (Previously presented) The method of claim 6, wherein the effective amount of the mecamylamine or mecamylamine stereoisomer is 0.005-1.00 mg/kg/day.
9. (Previously presented) A method of treating cognitive deficits in learning and memory associated with age-related cognitive disorders in an individual in need thereof, the method comprising administering to the individual an effective amount of a mecamylamine or a mecamylamine stereoisomer.
10. (Previously presented) The method of claim 9, wherein the mecamylamine or mecamylamine stereoisomer is dimethylamino mecamylamine.
11. (Previously presented) The method of claim 9, wherein the effective amount of the mecamylamine or mecamylamine stereoisomer is 0.005-1.00 mg/kg/day.
12. (Previously presented) The method of claim 9 in which the cognitive deficits in learning and memory are caused or exacerbated by therapy using conventional neuroleptic drugs.

13. (Original) The method of claim 9 additionally comprising administering an atypical neuroleptic drug.
14. (Canceled)
15. (Currently amended) The method of claim 2 1, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
16. (Currently amended) The method of claim 2 1, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
17. (Currently amended) The method of claim 2 1, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
18. (Currently amended) The method of claim 2 1, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
19. (Currently amended) The method of claim 2 1, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.
20. (Currently amended) The method of claim 2 1, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
21. (Currently amended) The method of claim 2 1, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.
22. (Currently amended) The method of claim 2 1, wherein the mecamlamine or mecamlamine stereoisomer is administered in a sustained or delayed release dosage form.
23. (Currently amended) The method of claim 2 1, wherein the mecamlamine or mecamlamine stereoisomer is administered by bronchial inhalation.
24. (Currently amended) The method of claim 7 6, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
25. (Currently amended) The method of claim 7 6, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
26. (Currently amended) The method of claim 7 6, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
27. (Currently amended) The method of claim 7 6, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
28. (Currently amended) The method of claim 7 6, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.

29. (Currently amended) The method of claim 7 6, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
30. (Currently amended) The method of claim 7 6, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.
31. (Currently amended) The method of claim 7 6, wherein the mecamlamine or mecamlamine stereoisomer is administered in a sustained or delayed release dosage form.
32. (Currently amended) The method of claim 7 6, wherein the mecamlamine or mecamlamine stereoisomer is administered by bronchial inhalation.
33. (Currently amended) The method of claim 10 9, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
34. (Currently amended) The method of claim 10 9, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
35. (Currently amended) The method of claim 10 9, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
36. (Currently amended) The method of claim 10 9, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
37. (Currently amended) The method of claim 10 9, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.
38. (Currently amended) The method of claim 10 9, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
39. (Currently amended) The method of claim 10 9, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.
40. (Currently amended) The method of claim 10 9, wherein the mecamlamine or mecamlamine stereoisomer is administered in a sustained or delayed release dosage form.
41. (Currently amended) The method of claim 10 9, wherein the mecamlamine or mecamlamine stereoisomer is administered by bronchial inhalation.
42. (Previously presented) A method for treating cognitive deficits in learning and memory in a patient suffering from executive dysfunction, the method comprising administering an effective amount of a mecamlamine or a mecamlamine stereoisomer.
43. (Previously presented) The method of claim 42, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.

44. (Previously presented) The method of claim 42, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
45. (Previously presented) The method of claim 42, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
46. (Previously presented) The method of claim 42, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
47. (Previously presented) The method of claim 42, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.
48. (Previously presented) The method of claim 42, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
49. (Previously presented) The method of claim 42, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.
50. (Previously presented) The method of claim 42, wherein the mecamlamine or mecamlamine stereoisomer is administered in a sustained or delayed release dosage form.
51. (Previously presented) The method of claim 42, wherein the mecamlamine or mecamlamine stereoisomer is administered by bronchial inhalation.
52. (Currently amended) A method for ~~treating~~ treating cognitive deficits in learning and memory ~~associated~~ in a patient suffering from attention deficit hyperactivity disorder, the method comprising administering an effective amount of a mecamlamine or a mecamlamine stereoisomer.
53. (Previously presented) The method of claim 52, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
54. (Previously presented) The method of claim 52, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
55. (Previously presented) The method of claim 52, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
56. (Previously presented) The method of claim 52, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
57. (Previously presented) The method of claim 52, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.

58. (Previously presented) The method of claim 52, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.

59. (Previously presented) The method of claim 52, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.

60. (Previously presented) The method of claim 52, wherein the mecamlamine or mecamlamine stereoisomer is administered in a sustained or delayed release dosage form.

61. (Previously presented) The method of claim 52, wherein the mecamlamine or mecamlamine stereoisomer is administered by bronchial inhalation.

62. (Currently amended) A method for treating cognitive deficits in learning and memory associated in a patient suffering from bipolar disorder, the method comprising administering an effective amount of a mecamlamine or a mecamlamine stereoisomer.

63. (Previously presented) The method of claim 62, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.

64. (Previously presented) The method of claim 62, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.

65. (Previously presented) The method of claim 62, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.

66. (Previously presented) The method of claim 62, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.

67. (Previously presented) The method of claim 62, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.

68. (Previously presented) The method of claim 62, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.

69. (Previously presented) The method of claim 62, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.

70. (Previously presented) The method of claim 62, wherein the mecamlamine or mecamlamine stereoisomer is administered in a sustained or delayed release dosage form.

71. (Previously presented) The method of claim 62, wherein the mecamlamine or mecamlamine stereoisomer is administered by bronchial inhalation.